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The Ras superfamily of G-proteins are of great research interest for structure-function 
relationships among proteins as they act as molecular switches in the regulation of various 
biochemical reactions in the cell. They are regulated by protein-protein interactions targeted to 
the highly flexible switch regions. Mutations in G-proteins or their effectors may cause 
alterations in structure and/or function that can lead to overactivity. 
The Ras-related protein Cell division cycle 42 (Cdc42) is important in regulating cell-
signaling processes. The T35A mutation in Cdc42 leads to a decrease in flexibility of the Switch 
I region responsible for effector binding 
3
.  The kinetics of the intrinsic GTP hydrolysis reaction 
were compared for Cdc42 (WT and T35A) in the absence and presence of a peptide derivative of 
PAK21 activated kinase (PBD46). The mutation does not affect the intrinsic GTP hydrolysis rate 
of Cdc42, but binding with PBD46 is altered by the mutation; in the presence of PBD46, GTP 
hydrolysis is completely inhibited for Cdc42 WT while partial recovery of GTP hydrolysis for 
Cdc42 T35A was observed in the presence of PBD46. The data obtained lead us to propose two 
slowly interconverting conformational states of Cdc42 T35A, both able to hydrolyze GTP, but 
one that shows a weakened affinity for PBD46.  
Ras homolog enriched in brain (Rheb) is a member of the Ras superfamily of proteins 
known to regulate cell growth and proliferation by signaling the mammalian target of rapamycin 
(mTOR) pathway. The Tuberous Sclerosis Complex 2 protein (TSC2) regulates Rheb by 
functioning as a GTPase activating protein (GAP).  At present, very little is known about the 
molecular features of the Rheb-TSC2 protein interaction. We present biochemical and 
biophysical data on the interaction of Rheb with TSC2 WT, using a shorter, 218 amino acid 
GTPase derivative of TSC2 (TSC2-218), as well as with the mutant TSC2-218 K114A, to 
characterize the TSC2-218 constructs and their GAP activity towards Rheb.  A decrease in 
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1 CHAPTER 1: INTRODUCTION 
1.1 RAS 
Structure-function relationships among proteins are crucial for evaluating the biological 
processes associated with these proteins.  Understanding the chemical and biological aspects of 
these interactions can give much insight into how therapeutic treatments may be developed to 
combat diseased-states such as cancer.  The Ras superfamily of G-proteins are of significant 
research interest as they act as molecular switches in the regulation of various biochemical 
reactions in the cell and are controlled via cycling between nucleotide-bound states
4
.  Their cell 
signaling activity is dictated by the bound nucleotide; a biologically active GTP-bound form and 
an inactive GDP-bound form.   
Ras proteins have been highly conserved through eukaryotic evolution 
5
.  Three ras genes 
have been identified in mammals, H-ras-1, K-ras-2, and N-ras, and are known as p21 
6-8
.  All 
known Ras proteins contain 85 identical amino acids at the amino terminus. The subsequent 80 
amino acids vary within the different proteins, although there is 85% homology between any pair 
of Ras proteins.  The last domain exhibits the most variation among Ras proteins, although the 
carboxyl terminus always ends in C-A-A-X-COOH, where A is any aliphatic amino acid; this is 
important so that the protein can be targeted to the periphery of the cell membrane after it has 
been biosynthesized by lipidation 
9
. 
Although comprised of multiple subfamilies with varying functions in the cell, Ras 
GTPases share similar structure in a G domain, the GTP/GDP binding domain 
10
.  This G domain 
includes the switch I, switch II and P loop regions (phosphoryl binding loop) 
11
.  Residues 25-40 
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Figure 1. G-protein GTP/GDP 
cycle. GAPs and GEFs regulate 
the active and inactive states. 
make up the switch I region and residues 57-75 make up the switch II region responsible for 
hydrophobic, polar, and charged interactions with the effectors 
12-15
.  Ras contains a highly 
conserved glycine (G12) in the P-loop 
11, 16
.  The nucleotide binding region exhibited in Ras 
GTP-binding proteins is highly conserved 
17
. The phosphate groups of the nucleotide interact at 










.  Mutation of the glycine at position 12 to anything other than proline leads to 
inherent activation 
20-22
, which can also occur if this residue is deleted or if insertions occur 
immediately before 
23
.  Changes in this residue disrupt the α-helical structure lead to improper 
folding 
24-26
. If the subsequent glycine (G13) is mutated to either valine or aspartic acid, 
oncogenic activity is induced in the protein 
27
.  Ras also contains a conserved glutamine residue 
(Q61) in the nucleotide binding domain that stabilizes the nucleotide and is, therefore, important 
for GTP hydrolysis 
28-30
.  This residue is the most 
frequently mutated residue in human cancers; 
replacement of leucine for this glycine increases the GTP 
bound levels by causing resistance to Ras GAP activity 
31
. The cycling between the GTP- and GDP-bound states 
of Ras GTPases is a result of the high affinity of the G 
domain for these nucleotides 
32
 and is catalyzed by 
regulatory proteins (Figure 1).  The GTP-GDP exchange 
is stimulated by guanine nucleotide exchange factors 
(GEFs), which interact at the switch I and switch II regions.  Upon binding to GTP, a 
conformational change is induced in Ras that favors protein-effector interactions that facilitate 
activity 
33
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conformational change that lowers the protein’s affinity for effectors, thereby causing 
inactivation.  Ras GAPs work to stabilize the conserved switch II glutamine responsible for 
stabilization of the hydrolytic water responsible for hydrolysis of the γ-phosphate through the use 
of an arginine residue that forms hydrogen bonds with a bridge oxygen atom of GTP 
31, 34, 35
.  
Guanine dissociation inhibitors (GDIs) stabilize the GDP-bound form of GTPases and prevent 
membrane localization 
36
.  Abnormal expression, often as a result of various mutations, in 
GTPases is responsible for a large proportion of cancer types.  Mutations often lead to a loss of 
GTPase activity which prolongs the GTP-bound conformation and keeps the GTPase in an 
uninterrupted active state; extended overactivity often results in cancer 
9, 37
.   Abnormal 
expression in Ras proteins have been implicated in up to 30% of human cancers 
37
.  For these 
reasons, the GTPases are hopeful drug targets for anticancer therapy.  
1.2 CDc42 
Cdc42 is a member of the rho subfamily of the Ras superfamily of GTPases, which plays 
significant roles in the regulation of cell proliferation and differentiation by binding to effectors; 
upon effector binding, a cascade of kinase interactions is activated. P21-activated kinase, a 
serine/threonine kinase, is one such kinase 
38
.  Like other Ras proteins, Cdc42 has the potential to 
signal overactivity if its active state is not regulated as GTP concentration in the cell is much 
higher than that for GDP 
38
.  A 46-amino acid peptide derived from PAK (PBD46) interacts with 
Cdc42 with high affinity 
38, 39
 and prevents GTP hydrolysis by stabilizing Cdc42 in the GTP-
bound state with a slow exchange rate 
38
.  This interaction, which occurs in the highly flexible 
switch I and switch II regions 
33, 38
, initiates a signaling cascade leading to the activation of 
multiple kinases 
40
.  PBD46  was derived from PAK1, one of the four subtypes of PAK, and 
NMR structures have revealed that, while unstructured in its free form, PBD46 undergoes a 
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conformational change upon binding to Cdc42 
41
. This conformational change is partnered with a 
decrease in flexibility exhibited in Cdc42 upon interaction 
38
. 
Structural studies on Cdc42 have identified 6 β-sheets, 5 α-helices and 10 loop regions 
42
.  
NMR solution studies have shown that PBD46 interacts primarily with a β-strand (β2) via an 
antiparallel intermolecular extension, as well as with portions of α1, α5, switch I, and switch II 
38, 
39, 41
.  Further NMR studies by Gizachew, et al. implied that the Cdc42-PBD46 interaction is 
stabilized by hydrophobic interactions and that the strong binding energy can be attributed to the 
interaction between the carboxylate group of glutamic acid at position 15 in PBD46 and the 
hydroxyl group of tyrosine at position 40 in Cdc42.   
The switch I and switch II regions are both highly flexible regions responsible for 
effector interaction.  Single point mutations involving various residues in the Switch I region 
have an effect on the effector binding of Ras proteins 
43
. The phenylalanine at position 28 is 
important as its aromatic ring stabilizes the nucleotide 
82-84
.  Mutation of phenylalanine to leucine 
at this position in Cdc42 (Cdc42 F28L) is referred to as a fast cycling mutant; it is characterized 
by an increased exchange rate between GTP and GDP 
85
.  This rapid exchange can be attributed 
to an increase in flexibility in the nucleotide binding site that lowers the affinity for the 
nucleotide 
85
; specifically, NMR studies indicated that the F28L mutation altered the binding site 
around the α and β phosphate groups of the nucleotide, but no modifications were seen around 
the γ phosphate 
17, 86
.  Also in the Switch I region of Cdc42, as with other Ras proteins, an 
invariant threonine at position 35 is critical for function.  Preliminary observation of a threonine 
to alanine point mutation at this residue (Cdc42 T35A) shows that, although the thermal stability 
is not effected, less effector binding occurs and this weakened interaction may be a result of the 
5 
 
loss of conformational freedom in the Switch I region, supported by solution structure backbone 
dynamics studies and biochemical characterization, due to the removal of the hydroxyl side chain 
of residue 35 
3, 44
.  Our hypothesis is that the weakened binding between Cdc42 T35A and 
PBD46 could restore the GTP hydrolysis activity characteristic of Cdc42.  We use a GTP 
hydrolysis assay to compare the intrinsic GTP hydrolytic activity of Cdc42 T35A to Cdc42 WT 
in the absence and presence of PBD46. The results show that both Cdc42 T35A and Cdc42 WT, 
in the absence of PBD46, demonstrate similar hydrolytic efficiency.  However, Cdc42 T35A still 
exhibits a fraction of GTP hydrolysis in the presence of PBD46 in contrast to the complete 
inhibition observed for WT.  The data suggest that there may be multiple slowly interconverting 
conformations of Cdc42 T35A that may have different or weakened interactions with PBD46.  
This study highlights the potential for development of a way to restrict flexibility as a means to 
control oncogenic protein-protein interactions.   
1.3 RHEB 
Rheb (Ras homology enriched in brain) proteins belong to the Ras superfamily of G-
proteins 
21, 45
.  Due to the cycling between GDP and GTP, as with other Ras proteins, Rheb must 
be regulated through protein-protein interactions.  Upon binding to GTP, a conformational 
change from the GDP-bound form is induced, which allows Rheb to regulate cell growth through 
its role in signaling through the insulin/TOR/S6K pathway 
46-50
.  Overall sequence similarity is 
seen between Rheb and Ras, with a few key differences 
49
.  Rheb contains an arginine (R15) at 
the position equivalent to the conserved glycine (G12) in Ras 
20-22
.  Substitution of glycine for 
arginine at position 15 in Rheb does not restore hydrolytic activity as would be expected for its 
equivalence in Ras
51
.  In Rheb, mutation of the homologous glutamine residue to leucine (Q64L) 
does not inhibit protein-protein interactions; this residue is catalytically useless, due to its buried 
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orientation in a hydrophobic pocket, and does not participate in GTP hydrolysis 
1, 45, 52
.  Due to 
these differences, Rheb has an intrinsically low rate of GTP hydrolysis and, as such, must be 
regulated by protein-protein interactions in order to prevent overactivity by remaining in the 
GTP-bound active state 
20, 53, 54
. Therefore, outlining the correlation between structure and 
function is crucial for understanding, at the molecular level, what underlies the onset of the 
diseased-state. 
The genes of the tuberous sclerosis complex, TSC1 and TSC2, were first identified as 
tumor suppressor genes 
55
.  The TSC1 gene encodes for the protein TSC1 (hamartin), which has 
a “coiled-coil” domain near its carboxy terminus; this domain binds with high specificity to a 
domain found at the amino terminus of TSC2 (tuberin) 
54, 56
.  TSC1 and TSC2 interact to form a 
heterodimer called the tuberous sclerosis complex (TSC).  The TSC1 and TSC2 proteins share 
limited homology with any other proteins 
57
 with the exception of the C-terminus of TSC2 which 
contains a highly conserved domain that is homologous to Rap1GAP 
55, 58
.  It was suggested that 
the GAP domain of TSC2 interacts directly with a GTPase in order to facilitate the tumor-
suppressing function of the complex 
54, 55, 59
.  Rheb was determined to be a direct target for TSC 
GAP activity 
45-47, 52, 55, 60
. The TSC1/TSC2 complex functions as a Rheb GAP; an interaction 
between Rheb and TSC2 mediates the mTOR pathway and therefore regulates cell growth and 
energy and nutrient levels (Figure 2).  An extensive search of the literature does not reveal the 
specific role of TSC1 in the Rheb/TSC2 interaction 
46, 50, 53, 55, 61, 62
, only that it is required for the 
stabilization of TSC2 against ubiquitination 
63, 64
.   As a GAP, TSC2 stimulates GTP hydrolysis 
in Rheb through what has been suggested to be a catalytic “asparagine thumb” based on the 
homology to Rap1GAP, which also functions via the “asparagine thumb” 
65-67
. TSC2 differs 
from its interaction in Rheb from other Ras GTPases and their GAPs in the presence of this 
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“asparagine thumb” as mentioned.  This interaction differs in that it is not characterized by the 
“arginine finger” motif present in the activation of other GTPases like Ras 
34
.  Incorporation of 
an arginine residue in place of the asparagine residue that resulted in complete loss of GAP 
function proved that TSC2 could not function via a RasGAP-like “arginine finger” mechanism 
45
. Therefore, it is necessary to outline the molecular features of the Rheb-TSC2 protein-protein 
interaction that are important in the regulation of cell-signaling pathways dictated by this 
interaction.     
          A truncated version of TSC2 containing the GAP domain (TSC2-218) has been shown to 
interact with Rheb in vitro 
45
.  Mutations in the GAP domain of TSC2 have been described as 
leading to the onset of tuberous sclerosis, a genetic disorder associated with benign tumors called 
hamartomas that are often accompanied by the onset of seizures and mental retardation, due to 
the function of the GAP domain to increase intrinsic Rheb GTP hydrolysis activity; when 
mutated, the GAP activity of TSC2 towards Rheb is altered 
46, 53-55, 68-70
 (Figure 3B). The 
underlying biological mechanism by which TSC2 catalyzes GTP hydrolysis is not yet completely 
understood, but examination of disease-associated GAP domain mutants of TSC2 can allow for 
the study of the molecular mechanism of TSC2 GAP activity.  Our hypothesis is that mutations 
in TSC2 are either unable to bind to Rheb, and therefore unable to function as GAPs, or they 
bind, but are unable to catalyze GTP hydrolysis.   
 Through the use of several biochemical and biophysical techniques including circular 
dichroism and differential scanning calorimetry, it is apparent that the K114A mutation in TSC2-
218 leads to a change in secondary structure and thermal stability; these structural differences, 
compared to WT, could explain the loss GAP activity towards Rheb seen in the kinetics studies 
and the lack of binding seen in the binding assays. Where TSC2-218 WT functions to stimulate 
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Rheb GTP hydrolysis, a very low rate, similar to that of Rheb, was seen for Rheb in the presence 
of TSC2-218 K114A, suggesting that either TSC2-218 K114A does not bind to Rheb at all or 
that it binds with no catalytic activity towards Rheb.  This study emphasizes the need to 
characterize the Rheb-TSC2-218 complex in order to get a detailed molecular picture of TSC2’s 
catalytic mechanism as there is minimal information on the Rheb-TSC2 interaction due to the 
lack of structural information on TSC2-218.        
9 
 
Figure 2. Schematic illustration of the TSC2-stimulated GTPase activity of Rheb. The 
activity of Rheb is controlled by the nucleotide-bound state; GTP-bound Rheb (1XTS.pdb) 
is active and GDP-bound Rheb (1XTQ.pdb) is inactive. The binding of TSC2 to active 
Rheb-GTP (1XTS.pdb) 
1
 stimulates hydrolysis which diminishes the mTOR activity. The 






Figure 3. Regulation, or lack thereof, of TSC2-stimulated GTPase activity of 
Rheb.  (A) TSC2-218 WT functions as a GAP for Rheb by facilitating GTP 
hydrolysis and inhibiting over-activity, represented by the longer dashed lines 
indicating a stronger interaction.  (B) Mutant TSC2-218 shows weaker or no 
binding to Rheb (shorter dashed lines) leading to abnormal cell-signaling activity 
or a loss of GAP activity. The structure of TSC2-218, currently unknown, was 








2 CHAPTER 2: EXPERIMENTAL 
2.1 PROTEIN GROWTH, EXPRESSION AND PURIFICATION   
2.1.1 CDC42 (WT AND T35A) 
Cdc42 constructs were overexpressed as His6-tagged fusion protein from pET15b in the 
Escherichia coli strain BL21 (DE3) in LB broth. A culture of LB containing 0.1 mg/mL 
ampicillin was grown overnight at 37°C.   This overnight culture was used to inoculate 1-2 liters 
of fresh LB and was allowed to grow with shaking at 37°C until the OD600 reached 0.6-0.8.  The 
cells were induced with a final concentration of 0.2 mM IPTG (isopropyl-β-D-
thioglactopyranoside) and allowed to express at 37°C for 4 hours.  After expression, the cells 
were harvested by centrifugation at 6,500 rpm for 20 minutes at 4°C. The pellet was resuspended 
in 10 mM Tris (pH 8.0) and centrifuged again. The cell pellets were stored at -80°C. 
To begin the purification process, each 1-liter pellet was thawed on ice and resuspended in lysis 
buffer (25 mL Tris/NaCl binding (40 mM imidazole, 100 mM NaCl, 50 mM Tris pH 8.0, 10 mM 
MgCl2), 25 mg lysozyme, Halt protease inhibitor cocktail to a final concentration of 0.5x, 
DNAse, and 1 mM PMSF).  Cells were lysed via sonication on ice (3 second pulse with 5 second 
pause, 40 repetitions). The cell debris and the soluble fraction were separated by centrifugation at 
18,000 rpm for 25 minutes at 4°C.  The cell lysate as well as Tris/NaCl binding buffer and 
Tris/NaCl
 
elution buffer (250 mM imidazole, 100 mM NaCl, 50 mM Tris pH 8.0, 10 mM 
MgCl2) were filtered before purification on AKTA FPLC using a 5-mL prepacked Ni
2+
 affinity 
column (GE Healthcare HiTrap His Column).  After the column was equilibrated with 5CV 
Tris/NaCl binding buffer, the cell lysate was loaded over the column.  A linear gradient was used 
to increase the imidazole concentration for elution of the purified protein.  The protein was either 
12 
 
dialyzed overnight at 4°C against the required buffer for the next experiment or lyophilized for 
storage.  For active Cdc42, Cdc42-His6 was nucleotide exchanged according to established 
procedures 
71
. Briefly, Cdc42-His6 was incubated with 5 mM EDTA and 0.5 mM GTP analog for 
3 hours at 4°C.  Following incubation, EDTA and excess nucleotide were removed with an 
equilibrated desalting column (GE Healthcare PD-10). 10 mM Mg
2+
 was replaced.   
2.1.2 PBD46 
PBD46, a peptide derivative of p21-activated kinase, was expressed as a GST fusion protein 
from pGEX-2T in the E. coli strain BL21 (DE3) in LB broth to OD600 0.8-1.0 and induction with 
0.5 mM IPTG for 5 hours at 37°C. GST-PBD46 was lysed as previously described for Cdc42, 
except that the binding buffer was PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4, pH 7.4) 
72
.  A GSTrap FF 5 mL prepacked column (GE Healthcare) eluted with an 
isocratic gradient of glutathione elution buffer (10 mM reduced glutathione, 20 mM Tris pH 8.0) 
was used in purification.   
As the GST tag is quite large (26 kDa), it was necessary to cleave off the tag.  Thrombin 
recognizes a specific amino acid sequence between PBD46 and the GST tag. PBD46 was 
cleaved from the GST tag by incubation with thrombin (Sigma) for 5 hours at 4°C. After 
incubation, Halt protease inhibitor was added to stop cleavage.  The product was dialyzed in PBS 
(pH 7.4) before loading onto a regenerated GST column as before to remove the GST tag.  
2.1.3 RHEB 
Residues 1-169 of Rheb were overexpressed as a His6-tagged fusion protein as described for 
Cdc42 (page 11) using PBS Ni
2+
 binding (PBS pH 8.0, 50 mM MgCl2, and 25 mM imidazole) 
and PBS Ni
2+
 elution (PBS pH 8.0, 50 mM MgCl2, and 400 mM imidazole) buffers.  
13 
 
Figure 4. GST-TSC2-218 Test Expression. After inoculated with overnight 
culture, samples were expressed according to conditions in table. Pre-induced 
sample (PI) taken at OD600 0.6. Condition C (OD600 0.8-1.0, 0.5 mM IPTG, room 
temperature expression for 5-6 hours) yields the highest expression of GST-TSC2-
218 in the soluble fraction (demarked by black box). 
For active Rheb, Rheb-His6 was nucleotide exchanged for one hour at room temperature.   
2.1.4 TSC2-218 WT 
As successful growth and overexpression of the GAP domain of TSC2 (TSC2-218) as a GST 
fusion protein from pGEX-2T in the E. coli strain BL21 (DE3) in LB broth had not yet been 
achieved in the lab, it was necessary to optimize these conditions.  Existing stocks were used to 
streak agar plates containing ampicillin and allowed to grow overnight at 37°C.  Isolated 
colonies were used to inoculate LB containing ampicillin.  After expression (Figure 4), 1 mL 




was then resuspended in 100 μL lysis buffer (PBS (pH 7.4), 10 mM MgCl2, and 0.1 mg/mL 
lysozyme). The soluble and insoluble fractions were then separated; the suspension was 
sonicated briefly and exposed to a freeze-thaw method of lysis.  Centrifugation separated the 
soluble (supernatant) and insoluble (pellet) fractions.  The pellet was resuspended in 8M urea.  
2X sample dye (100 mM Tris (pH 6.8), 4% SDS, 20% glycerol, 200 mM BME, and 0.2% 
bromophenol blue) 
72
 was added to each sample before running on 15% SDS-PAGE.  The 
density of each band corresponding to the molecular weight of GST-tagged TSC2-218 (51 kDa) 
represented a direct correlation to the amount of expression.  Growth to OD600 0.8-1.0 and 
induction with 0.5 mM IPTG at room temperature for 5-7 hours gave the highest yield of protein 
in the soluble fraction.   
GST-TSC2-218 was lysed as previously described for GST-PBD46. To determine the necessary 
time required for cleavage, thrombin was added to the protein sample (1 unit thrombin per 150 
μg protein) and incubated at 4°C. After each hour, a sample was removed and Halt protease 
inhibitor added to stop cleavage. After 4 hours, each sample was run on SDS-PAGE (Figure 5).  
TSC2-218 was cleaved from the GST tag by incubation with thrombin for 1-2 hours at 4°C as 
described (page 12).  
2.1.5 TSC2-218 K114A 
Using Qiagen Plasmid Prep Kit, a plasmid of TSC2-218 was prepared from a 5-mL overnight 
culture.  The DNA concentration was determined via UV Vis at 260 nm.  Once obtained, the 
DNA was submitted with pGEX 3’ primer and pGEX 5’ primer to University of Arkansas DNA 
Resource Center for sequencing.  When the sequence of TSC2-218 WT was confirmed, primers 
were designed to make the lysine to alanine point mutation at position 114.  When designing the 
primers for product TSC2-218 K114A, it was important that the primer sequence had minimal 
15 
 
Figure 5. SDS-PAGE of thrombin cleavage experiment. Lane 1 shows the 
molecular weight marker. Lane 2 shows the GST-tagged TSC2-218 control. 
Lanes 3-6 show the thrombin cleavage products after 1-4 hours, consecutively. 
Thrombin cleavage is complete after 1 hour. 
secondary structure, would not form a primer dimer, and that it had an acceptable G-C content 
reflected by the melting point.  The codon AAG translates to lysine and alanine is coded by 
GCT, GCC, GCA, and GCG. The mutation of AAG to GCG was chosen as it requires the fewest 
nucleotide changes.  OligoAnalyzer (IDT) was used to monitor the various combinations of 
primers for the optimal sequence. The forward and reverse primers used were:  
Forward: CGACAAGGCGCGCCACCTGGG      Reverse:  CCCAGGTGGCGCGCCTTGTCG 
DNA calculator (Sigma) was used to analyze the primers for Tm, GC content, secondary 
structure, and the likelihood of primer dimer formation; both primers show weak secondary 
structure, no primer dimer, and have a Tm of 81.21 °C.   
16 
 
Table 1. PCR settings for site-directed mutagenesis. The 
kilobases of DNA for the protein and the primer totaled 
5.638 kb. The time for the 68°C cycle of segment 2 was 
set at 7.638 minutes. 
A Quick Change Site Directed Mutagenesis Kit II (Stratagene) was used to form the point 
mutation.  The sample was prepped according to the kit; 5 μL 10X reaction buffer, 5-50 ng 
dsDNA, 125 ng primer 1 (forward primer), 125 ng primer 2 (reverse primer), and1 μL dNTP mix 
were combined and made to 50 μL with sterile water followed by the addition of 1 μL DNA 
polymerase.  The parameters on the PCR cycler are shown in Table 1.  The amplified PCR 
product was digested by addition of DpnI restriction enzyme and 1 hour incubation at 37°C.  A 
transformation into BL21 (DE3) competent cells immediately followed. This new construct was 






Plasmid prep was again prepared and DNA submitted for sequencing. Sequencing results 
showed that the point mutation was successful. 
A test expression was repeated as described before (see page 13) to determine growth and 
expression conditions for GST-TSC2-218 K114A as the mutation may have altered expression in 
comparison to TSC2-218 WT.  GST-TSC2-218 K114A was expressed at room temperature for 5 
Segment Cycle Temperature (°C) Time 
1 1 95°C 30 seconds 
2 18 95°C 30 seconds 
  55°C 1 minute 
  68°C 2 min + (
1 min
/kilobase DNA) 
Set to hold at 4°C 
17 
 
hours after induction with 0.5 mM IPTG.  Purification was identical to that for GST-TSC2-218 
WT. 
2.2 IN VITRO BINDING ASSAYS  
Rheb-His6 was nucleotide exchanged according to previous protocols 
71
 (page 12) using 
GMPPCP (Sigma). Equimolar Rheb-His6-GMPPCP and GST-TSC2-218 were incubated 
together at 4°C for 12-16 hours. The sample was concentrated to 1 mL and purified using size-
exclusion chromatography.  A HiPrep 16/60 Sephacryl S-100 HR column (GE Healthcare) was 
used on AKTA FPLC.  10 microliters of each concentrated fraction was run on a 15% SDS-
PAGE.  The in vitro binding assays were performed in triplicate.   
2.3 CIRCULAR DICHROISM 
Circular dichroism measurements were performed on a Jasco J-710 Spectropolarimeter.  CD 
spectra of purified protein samples were measured in the far-UV range (190-250 nm) in a 0.2 
mm pathlength quartz spectrophotometer cell.  Spectra were measured at 50 nm/min.  The 
concentration of protein solutions used for the CD measurements was 0.5 mg/mL in 10mM 
phosphate buffer (pH 7.0).  For difference spectra, the protein and ligand protein were combined 
in a 1:1 ratio. Spectra Manager was used to collect the data in triplicate.  10 spectra were 
obtained for each sample.  From each spectrum, the spectrum of the buffer was subtracted using 
Spectra Manager. For the difference spectra, the spectrum of the ligand protein was subtracted.   
2.4 DIFFERENTIAL SCANNING CALORIMETRY 
Differential scanning calorimetry measurements were performed using an N-DSC III Differential 
Scanning Calorimeter (Calorimetry Sciences Corporation).  Purified protein concentrations of 1-
2 mg/mL were dialyzed extensively at 4°C in 10 mM phosphate buffer at pH 7.4.  Spectra of the 
18 
 
protein were recorded over a temperature range between 10 and 100°C at a heating rate of 
2°C/min after degassing of the sample.  A baseline obtained using the buffer was subtracted from 
the protein spectra. Each protein sample was scanned in triplicate. CpCalc (Calorimetry Sciences 
Corp) was used to obtain the melting curve and determine the Tm. 
2.5 PROTEOLYTIC DIGESTION 
Chymotrypsin (Sigma-Aldrich) and sodium dodecyl sulfate (J.T. Baker) were of molecular 
biology or ultrapure grade.  Limited proteolytic digestion experiments on TSC2-218 were carried 
out at 25°C in 10 mM HEPES pH 8.0 in the presence of 10 mM CaCl2. Proteolytic digestions 
were performed in triplicate at an enzyme (chymotrypsin) to substrate (TSC2-218) molar ratio of 
1:15. The protease activity was stopped after desired time intervals by the addition 1% SDS and 
the pH adjusted to 2.0 by the addition of 1 μL 12.1 M hydrochloric acid (EMD) and heating for 5 
minutes at 100°C to abolish all enzyme activity 
73, 74
. The degree of proteolytic cleavage was 
measured from the intensity of the 24 kDa band on a 15% SDS−PAGE gel corresponding to the 
untreated protein (TSC2-218) using UN-SCAN-IT gel 6.1 software. The intensity of the 
protease-untreated 24 kDa band (TSC2-218) was used as the control for 100% protection against 
proteolytic digestion. Chymotrypsin control concentration was verified by UV-absorbance at 280 
nm. 
2.6 GTP HYDROLYSIS ASSAY   
GTP hydrolysis assays were carried out to characterize differences of hydrolytic activity of WT 
vs mutant proteins for the Cdc42-PBD46 and Rheb-TSC2-218 interactions. 
All chemicals were ultrapure or of molecular biology grade and all chemical solutions were 
prepared fresh before each assay.  The Ras protein (Rheb or Cdc42) was nucleotide exchanged 
19 
 
using GTP by incubating the protein with freshly prepared 0.5 mM GTP (Sigma) and 5 mM 
EDTA (EMD) to remove bound Mg
2+
.  EDTA and any excess nucleotide were removed by 
passing through a PD-10 desalting column (GE Healthcare) and then 10 mM MgCl2 was added to 
the protein solution to incorporate Mg
2+
 back on the protein.  The Ras protein bound to GTP was 
immediately passed over a PD-10 column again to remove any endogenously hydrolyzed Pi 
released prior to the GTP hydrolysis assay.   
Time-dependent GTP hydrolysis was performed with TSC2-218 using a 1:2.5 molar ratio of 
GTP-bound Rheb (10 μM) to TSC2-218 (25 μM). To initiate hydrolysis, each protein mixture 
was mixed with 2 mM GTP in 10 mM HEPES pH 8.0 (J.T. Baker) to a final volume of 1 mL and 
incubated at 25°C.  For measuring GTP hydrolysis as a function of time, the hydrolysis was 
stopped after desired time intervals (0, 10, 20, 30, 45, 60, and 90 min) via protein denaturation 
by the addition of 6% SDS (J.T. Baker).  For the GTP hydrolysis assay as a function of TSC2-
218 concentration, 10 μM Rheb was incubated with TSC2-218 at varying concentrations for 30 
minutes, and the hydrolysis measured at each concentration of TSC2-218. To monitor GTP 
hydrolysis, 6% ascorbic acid and 1% ammonium molybdate (Sigma) were added to the protein 
mixture, followed by 3-7 minute incubation at room temperature.  Sodium citrate (Sigma), 
sodium metaarsenite (J.T. Baker), and acetic acid (EMD) (1% each) were added to the denatured 
protein mixture and incubated for an additional 20 minutes and then assayed for any color 
changes at 850 nm according to established methods (Figure 6) 
75, 76
.  To calibrate the assay, 
GTP was added after protein denaturation and the absorbance of this sample was read and 
subtracted from the desired sample absorbance at each time point. Using K2HPO4 as a phosphate 
source, 0-75 nM phosphate was assayed in triplicate to generate a linear standard curve used to 



























































































































































































































































































































































































































determined by averaging the values from triplicate experiments and calculating the difference for 
each time point from the time-zero value.  To measure GTP hydrolysis of Cdc42 (WT and 
T35A), the Cdc42 was assayed in the absence and presence of PBD46 as a function of time and 
as a function of PBD46 concentration as described for the Rheb-TSC2-218 interaction.  
 2.7 2D-HSQC NMR   
2.7.1 SAMPLE PREPARATION 
To initiate growth, an overnight culture of either Rheb or TSC2-218 was grown in LB. The cells 
were pelleted via centrifugation and washed twice with NMR buffer (10 mM NaH2PO4, 5 mM 
MgCl2, and 100 mM NaCl). The cells were resuspended in unlabeled M9 minimal media (47.8 
mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.7 mM NH4Cl, 2 mM MgSO4, 0.1 mM CaCl2, 
and 0.4% glucose supplemented with a vitamin solution (.325 mg each of pantothenoic acid, 
choline chloride, folic acid, myo-inositol, nicotinamide, pyridoxyal hydrochloride, and 
riboflavin) and 25 mg/L thiamine) 
72
 and allowed to grow overnight. The overnight culture was 
used to inoculate fresh M9 media and monitored for the highest expression yield. 
15
N Rheb and 
15
N TSC2-218 were overexpressed in 
15
NH4Cl enriched minimal medium according to the 
demarcation in Figures 7 and 8, respectively, by induction with IPTG at room temperature. 
Purification was the same as for unlabeled samples (pages 12-14).   
2.7.2 SPECTRA ACQUISITION  
2D NMR experiments were performed on a Bruker Avance-500 MHz or 700 MHz NMR 
spectrometer at 25°C using TopSpin NMR.  500 μL of 0.1-0.5 mM labeled was dialyzed (Tube-
O-DIALYZER from G Biosciences) in NMR buffer (10 mM NaH2PO4, 5 mM MgCl2, 100 mM  
 






N-GST-TSC2-218 WT Test Expression. Samples were expressed 
according to conditions in table. All samples expressed for 16 hours. Condition C 
(OD600 0.7, 0.5 mM IPTG, room temperature expression) yields the highest expression 
of 
15




N Rheb Test Expression. 
15
N-Rheb Test Expression. Samples were 
expressed according to conditions in table. All samples expressed for 16 hours. 
Condition F (OD600 0.4, 1.0 mM IPTG, room temperature expression) yields the 
highest expression of 
15








Figure 9.  PBD46 concentration dependent GTP 
Hydrolysis. 10 μM Cdc42 (WT and T35A) 
(black and red, respectively) was assayed in the 
presence of increasing concentrations of PBD46. 
Saturation of Cdc42 WT occurs at 10 μM 
PBD46 ([Cdc42 WT]:[PBD46] = 1:1), at which 
point GTP hydrolysis is completely inhibited. 
Saturation of Cdc42 T35A occurs at 16 μM 
PBD46 ([Cdc42 WT]:[PBD46] = 1:1.6). T35A 
hydrolysis is only inhibited ~70% compared to 
100% inhibition of WT hydrolysis at PBD46 
saturation. 
3      CHAPTER 3: RESULTS AND DISCUSSION 
3.1 INTRINSIC GTP HYDROLYSIS IS OBSERVED FOR A SWITCH I MUTANT OF CDC42 IN THE 
PRESENCE OF A SPECIFIC GTPASE INHIBITOR PEPTIDE DERIVATIVE 
Studies on the conformational flexibility of a Cdc42 mutant show that with decreased 
flexibility, Cdc42 T35A binds to effector proteins less 
3
.  As previously described, PBD46 
prevents GTP hydrolysis of Cdc42 
38
. To compare the effects of the hydrolysis of Cdc42 T35A 
to Cdc42 WT, we examined the GTP hydrolysis of Cdc42 (WT and T35A) both alone and in the 
presence of PBD46.  Shown in Figure 9, a linear decrease in Pi released was seen for both 
Cdc42 WT and T35A, although variation 
is seen in the slopes. At a concentration of 
10 μM PBD46, where the [Cdc42 
WT]:[PBD46] = 1:1, total inhibition of 
GTP hydrolysis is seen. The saturation 
point for Cdc42 T35A was seen at 
approximately 16 μM PBD46, 1:1.6   
[Cdc42 T35A]: [PBD46]. Further addition 
of PDB46 does not have an effect on the 
GTP hydrolysis of activity of Cdc42 T35A 
above this saturation point.    
 A time-dependent GTP hydrolysis 
assay of 10 μM Cdc42 (WT and T35A) in 
the absence and presence of 30 μM PBD46 
25 
 
Figure 10.  Time-dependent Cdc42 GTP 
Hydrolysis Assay. 10 μM Cdc42 (WT and 
T35A) was assayed in the absence and 
presence of 30μM PBD46 (1:3 
[Cdc42]:[PBD46]. Cdc42 WT and T35A 
show comparable GTP hydrolysis. In the 
presence of PBD46, intrinsic GTP hydrolysis 
is completely inhibited for Cdc42 WT. Cdc42 
T35A exhibits partial restoration of 
hydrolysis in the presence of PBD46.  
was used to calculate and compare GTP hydrolysis rates according to the following equation: 
              (           
      ) 
where Pi(t) is the amount of inorganic phosphate released as a function of time (t), Pi(max) is the 
maximum amount of inorganic phosphate released, and kobs is the apparent first-order rate 
constant (Figure 10).  Consistent with 
previous results 
38
, Cdc42 WT showed a 
high rate of GTP hydrolysis (95.5 ± 4.8 
nmol Pi released) after 90 minutes in 
comparison to Cdc42 WT in the presence 
of PBD46 (0 nmol Pi released).  As there 
was no hydrolysis, this supports previous 
observations that PBD46 inhibits 
hydrolysis of Cdc42 WT.  Examination of the T35A mutation in the absence of PBD46 showed 
similar results to WT after 90 minutes (92.6 ± 
5.4 nmol Pi released), translating to similar 
first-order rate constants (0.0868 ± 0.0044 
min
-1
 and 0.0839 ± 0.0086 min
-1
, 
respectively).  Upon addition of PBD46, 
hydrolysis was partially restored for Cdc42 
T35A (32.5 ± 4.3 nmol Pi released) with a 
slower first-order rate constant of 0.0459 ± 0.0047 min
-1




Table 2. Pi max and Kobs for Cdc42 (WT and T35A) in 
the absence and presence of PBD46 determined via a 





Although the T35A mutation does not appear to affect the intrinsic GTP hydrolysis rate 
for Cdc42 in comparison to WT, the partial restoration of GTP hydrolytic activity in the presence 
of PBD46 observed for the T35A mutation can be attributed to the weaker binding affinity 
between the GTPase and its effector. This exhibits a link between the conformational flexibility 
and effector binding; the more rigid switch I region of Cdc42 T35A binds more weakly to 
PBD46, partially restoring GTP hydrolysis. 
Our results show that, as a result of this weaker binding, some of the intrinsic GTP 
hydrolysis is restored in the presence of the GTPase inhibitor PBD46.  The different slopes of the 
linear decrease in Pi released at low PBD46 concentrations for Cdc42 WT and Cdc42 T35A 
(Figure 9) are evidence that Kd for PBD46 binding to Cdc42 T35A is lower than that observed 
for WT, which is approximately 20 nM 
38
.  The difference in Kobs, taken together with the 
difference in Pi max observed for Cdc42 T35A in the presence of PBD46 compared to Cdc42 WT  
 Pi max (nmol) Kobs (min
-1
) 
Cdc42 WT 95.5 ± 4.8 0.0868 ± 0.0044 
Cdc42 WT + PBD46 N/A  
Cdc42 T35A 92.6 ± 5.4 0.0839 ± 0.0086 






in the presence of PBD46, is telling of two conformations of Cdc42 T35A that have slow 
interconversion rates (Figure 11B), which is an idea that has been hypothesized for Ras T35A 
33
.  
Although both conformations of Cdc42 T35A are capable of hydrolyzing GTP, one form has 
weakened or diminished binding to PBD46 which prevents PBD46 from completely inhibiting 
hydrolysis.   The first order rate constants are the same for Cdc42 WT and T35A in the absence 
of PBD46, seen in TABLE 2, as a result of kinetics studies (Figure 10); this supports the 
proposed model of interconverting T35A conformational states that are both capable of 
exhibiting intrinsic GTP hydrolysis. 
Figure 11. Proposed Cdc42 Kinetic Scheme. (A) Upon Cdc42 WT 
binding to PBD46, complete inhibition of GTP hydrolysis occurs as a 
result of tight binding. (B) Upon saturation of PBD46, Cdc42 T35A 
shows a reduced amount of hydrolysis compared to that in the absence of 
PBD46, but complete inhibition is not seen, implying that there may be 
two interconverting conformational states with different binding affinities 
to PBD46.  
28 
 
Figure 12. In vitro binding pull-down assay.   Lanes 1 and 2 
show the GST-TSC2-218 WT and Rheb controls, respectively. 
Lane 3 shows the molecular weight marker. Lane 4 shows the 
GST-TSC2-218-Rheb mixture before incubation. Lanes 5-8 
show subsequent washes. Lanes 9 and 10 show subsequent 
elutions. In the final wash before elution (lane 8), there is little 
to no protein shown. In the first elution (lane 9), bands 
representative of both Rheb and GST-TSC2-218 appear. 
Because glutathione beads were used, the only way for Rheb 
to appear in the elution is if it were bound to GST-TSC2-218, 
which bound to the beads. This confirms complex formation. 
3.2 CHARACTERIZATION OF THE INTERACTION BETWEEN RHEB AND TRUNCATED TUBEROUS 
SCLEROSIS COMPLEX 2 CONSTRUCTS  
The GAP domain of TSC2 is highly conserved across many species ranging from yeast to 
human 
77, 78
. This GAP domain binds to Rheb in vitro and in vivo.   Mutations in the GAP 
domain have been described as leading to the onset of the diseased state of tuberous sclerosis, 
due to the function of the GAP domain to increase intrinsic GTP hydrolysis activity of Rheb 
46, 
53-55, 68-70
 (Figure 2).  Neither the underlying mechanism by which TSC2 catalyzes GTP 
hydrolysis nor the details of the protein interaction are yet completely understood.  
As a control, we confirmed binding between Rheb and TSC2-218 through an in vitro binding 
assay of GST-tagged 
TSC2-218 with Rheb.  The 
concept lies in using the 
affinity tags to identify 
protein interactions.  If any 
untagged protein appeared 
in the elution, it would show 
that the proteins were in 
complex.  The specific GST-
tag was exploited. One of 
multiple assays showed 
complex formation 
(FIGURE 12).  In the 
elution peak, a band for 
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GST-TSC2-218 (51 kDa) and a band for Rheb (21 kDa) appear.  Rheb did not appear in the last 
wash before the elution; this leads to the conclusion that the only way Rheb could appear in the 
elution is if it was bound to GST-TSC2-218. Rheb alone does not bind to the glutathione 
sepharose.  Size-exclusion chromatography, which separates protein systems based on size, was 
next applied.  The large complex (72 kDa) would elute before the unbound GST-TSC2-218 and 
Rheb (51 kDa and 21 kDa, respectively) (Figure 13A).    
It was necessary to use GST-tagged TSC2-218 in order to separate the complex from both 
unbound samples due to the resolution limits of the column.  When the complex peak was run on 
SDS-PAGE, one band does not appear at the complex molecular weight (72 kDa), but rather a 
band appears representing each individual protein of the complex; the composition of the sample 
dye used for SDS-PAGE breaks the complex into its separate components.  The approximately 
Figure 13. In vitro binding assay of equimolar GST-TSC2-218 WT and Rheb. (A) FPLC 
size exclusion chromatogram showing complex (peak 2), unbound GST-TSC2-218 (peak 3), 
and unbound Rheb (peak 4). (B) SDS-PAGE results following size exclusion chromatography. 
The first three lanes represent the control of GST-TSC2-218 WT and Rheb, respectively, 
followed by the molecular weight marker. Lane 3 contains the molecular weight marker. Lanes 
labeled 1-4 represent peaks 1-4 from the chromatogram showing the absence of protein, 
complex, unbound GST-TSC2-218, and unbound Rheb, respectively. 
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Figure 14. In vitro binding assay of equimolar GST-TSC2-218 K114A and Rheb. (A) FPLC 
size exclusion (S100) chromatogram showing unbound GST-TSC2-218 K114A (peak 1), 
unbound Rheb (peak 2), and lack of complex formation. (B) SDS-PAGE results following size 
exclusion chromatography. The first two lanes represent the control of GST-TSC2-218 K114A 
and Rheb, respectively, followed by the molecular weight marker.  Lanes labeled 1 and 2 
correspond to peaks 1 and 2 from the chromatogram showing unbound GST-TSC2-218 K114A 
and unbound Rheb, respectively.  There is no complex formation. 
equal intensities of unbound GST-TSC2-218 and Rheb suggest that the binding is 1:1 as the 
assay was done with equimolar starting concentrations of the proteins (Figure 13B). 
Once our controls had been established, a tuberous sclerosis associated single point 
mutation was designed. The K114A (K138A in full-length TSC2) substitution has been observed 
in tuberous sclerosis patients and so it was of interest to investigate what effects this point 
mutation had on the TSC2-218 – Rheb interaction and GAP function of TSC2-218 
79
. Other 
point mutations at this residue eliminated GAP activity 
45
. Once expression and purification of 
TSC2-218 K114A were achieved, an in vitro binding assay with Rheb was done. The proteins 
were loaded onto a size-exclusion column as done for WT (page 14) (Figure 14).  An elution 
peak for unbound GST-TSC2-218 WT as well as for Rheb was seen.  However, unlike with 
wild-type TSC2-218, no complex formation was observed with TSC2-218 K114A (FIGURE 
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14A), evidenced by the lack of peak at 45 mL elution. This preliminarily shows that TSC2-218 
K114A does not interact with Rheb and, therefore, cannot act as a GAP to regulate cell signaling.  
Circular dichroism (CD) and differential scanning calorimetry (DSC) were used to 
characterize the TSC2-218 mutant in comparison to the wild-type.  TSC2-218 WT shows slight 
secondary structure, but a change in secondary structure is seen in TSC2-218 K114A (Figure 
15A).  The difference in secondary structure of the K114A mutant parallels a 5°C decrease in 
thermal stability as compared to 
WT (TSC2-218 unfolds at 60.6 ± 
0.32°C and TSC2-218 K114A at 
55.5 ± 0.42°C)  (Figure 16). A CD 
comparison of TSC2-218 WT in 
the absence and presence of Rheb 
shows that upon binding to Rheb, 
there is a slight change in the 
secondary structural features of 
TSC2-218 WT (Figure 15B), 
possibly supporting some form of an induced-fit model of binding.  Conversely, there is no 
change evident in TSC2-218 K114A in the presence or absence of Rheb (Figure 15C).  As 
changes in secondary structure were induced by the single-point mutation, a limited 
chymotrypsin digestion assay was used to monitor for any differences in cleavage patterns when 
exposed to chymotrypsin at an enzyme to protein ratio of 1:15.   As Figure 17 shows, different 
cleavage patterns were seen for WT and K114A, resulting in cleavage of 14% of TSC2-218 WT 
Figure 16. Differential Scanning Calorimetry.  TSC2-
218 WT exhibits a Tm of 60.6 ± 0.32°C. A 5°C decrease 
in thermal stability of TSC2-218 K114A is seen with a 
Tm of 55.5 ± 0.42°C. 
A       B 
 
 
































































































































































































































































































































































































Figure 18.  Time-dependent Rheb GTP 
Hydrolysis Assay. 10 μM Rheb was assayed in the 
absence and presence of 30μM TSC2-218 (WT 
and K114A) (1:3 [Rheb]:[TSC2-218]). In the 
absence of TSC2-218, Rheb shows very little 
intrinsic hydrolysis over time, displaying its 
characteristic “locked” GTP-bound state. Upon 
addition of TSC2-218 WT, GTP hydrolysis is 
facilitated. In the presence of TSC2-218 K114A, 
no increase in hydrolysis is seen in comparison to 
Rheb alone.  
and only 9.8% cleavage of TSC2-218 K114A after 180 minutes exposure to chymotrypsin 
activity.  As chymotrypsin cleaves at the carboxylic side of aromatic amino acids, no change 
would be expected in cleavage patterns unless a conformational change was induced; some 
conformational change imparted by the K114A mutation leads to slight protection from 
enzymatic cleavage. 
Rheb differs from other Ras proteins in that it has an intrinsically low rate of GTP hydrolysis and 
requires regulation to prevent overactivity; the activity of TSC2-218 WT as a GAP functions to 
regulate this activity by facilitating GTP hydrolysis 
55
. In order to compare the TSC2-stimulated 
GAP activity of Rheb between TSC2-
218 WT and K114A, we examined the 
GTP hydrolysis of Rheb alone and in the 
presence of TSC2-218 (Figure 18).  
Consistent with previous results 
45
, Rheb 
showed essentially no intrinsic GTP 
hydrolysis (6.8997 ± 2.4703 nmol Pi 
released). After 120 minutes, Rheb in the 
presence of TSC2-218 WT released 
61.7143 ± 1.3788 nmol Pi with a T½ of 
23.1 minutes compared to 6.8997 ± 
2.4703 nmol Pi released in the absence of 
TSC2-218 WT (Table 3).  In the 































































































































































































































































Figure 19.  TSC2-218-concentration dependent 
GTP Hydrolysis Assay. 10 μM Rheb was 
assayed for 30 minutes in the presence of 
increasing concentrations of TSC2-218 (WT and 
K114A). The binding constant and Hill 
coefficient were calculated from the Rheb – 
TSC2-218 WT curve.
 
Table 3.  T½  and rate constant for Rheb GTP Hydrolysis. 
Comparable values were obtained via the molybdate method 
used here (
B









increase in GTP hydrolysis was evident (7.4167 ± 0.8124 nmol Pi released). 
A concentration-dependent GTP 
hydrolysis assay of 10 μM Rheb in the 
presence of increasing concentrations of 
TSC2-218 (WT and K114A) was used 
to compare GTP hydrolysis according to 
the following equation: 
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where Pi is the amount of inorganic 
phosphate released, K is the apparent 
association constant, and n is the Hill 
coefficient, which gives an idea of 
cooperativity and may give information on 
the number of ligand binding sites  
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(Figure 19). The TSC2-218 WT – Rheb interaction released a maximal 44.4 ± 1.2 nmol Pi with a 
binding constant, K, of 5.4 ± 0.11 μM and a Hill coefficient of 5.3 ± 0.4.  The positive Hill 
coefficient (5.3 ± 0.4) calculated from the sigmoidal kinetics studies (Figure 19) implies that 
there may be more than one binding domain for TSC2-218-Rheb binding. 
2D HSQC NMR spectroscopy was used to determine if chemical shift changes occurred in 
15
N-labeled Rheb in the absence and presence of TSC2-218. A 2D HSQC overlay of 
15
N Rheb in 
the absence and presence of natural abundance TSC2-218 WT (Figure 20A) or TSC2-218 
K114A (Figure 20B) did not show any discernible chemical shift changes as also shown by 
Marshall, et al. 





N Rheb 2D HSQC NMR Spectroscopy. 15N Rheb was run in the absence (red) 
and presence of (A) TSC2-218 WT (black) and (B) TSC2-218 K114A (blue).  No chemical 
shift changes were evident in the presence of either TSC2-218 construct, although we know 
that binding occurs between Rheb and TSC2-218 WT. Spectra were obtained on Bruker 






N TSC2-218 WT 2D HSQC NMR Spectroscopy. 
15
N 
TSC2-218 WT was run in the absence (blue) and presence (red) of 
Rheb.  In both spectra, peaks characteristic of aggregation of 
evident. Spectra were obtained on Bruker Avance 700 MHz NMR 
using TopSpin and the data analyzed using Sparky Software.  
As there is no structural information to date on TSC2, it is of upmost importance to 
determine the structure to be able to fully characterize the TSC2-Rheb interaction.  Tremendous 
efforts have also been unsuccessful in many other labs to obtain a 2D HSQC of TSC2-218 
87
, 
perhaps due to the protein’s tendency to aggregate at high concentrations needed for NMR. 
Protein prediction software predicted the structure of TSC2-218 to consist of ~25% α helix, 
~25% β sheet, and ~50% random coil (Figure 22) 2. Our attempts at obtaining a spectrum proved 
to be quite difficult.  At lower TSC2-218 concentrations used for CD, DSC, etc., there were no 
problems with aggregation; at higher concentrations necessary for NMR, protein showed 
physical signs of aggregation in the NMR tubes, resulting in poor peak dispersion as evidenced 
in the spectra (Figure 21).  Efforts to obtain spectra at 15°C in the presence of 10% glucose did 
not improve and reduce aggregation (not shown).  We will continue to work with this protein and 
attempt change some aspects of the sample preparation in hopes to obtain an acceptable 
spectrum.   
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4      CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS 
4.1 INTRINSIC GTP HYDROLYSIS IS OBSERVED FOR A SWITCH I MUTANT OF CDC42 IN THE 
PRESENCE OF A SPECIFIC GTPASE INHIBITOR PEPTIDE DERIVATIVE 
Mutation of an invariant threonine residue in Cdc42, which causes a decrease in flexibility, 
does not affect the intrinsic GTP hydrolysis rate of Cdc42, but does alter the binding to an 
effector protein, PBD46. The disturbed binding leads to Cdc42 T35A GTP hydrolysis even in the 
presence of the GTPase inhibitor.  As a result of our studies, we proposed the presence of 
multiple interconverting conformational states of Cdc42 T35A, one of which has a decreased 
affinity for PBD46.    
Further characterization studies outlining the binding interface between PBD46 and Cdc42 
T35A could give insight into the molecular details that lead to the less dynamic switch I region 
and highlight specific residues that contribute to weaker binding as well and make available a 
target for the design of ways to regulate protein interactions and, therefore, abnormal cell 
signaling.  Fluorescence spectroscopy studies could be employed to study these two 
interconverting conformational states of Cdc42 T35A by calculating the KD and NMR 
spectroscopy could be used to outline the Cdc42 T35A – PBD46 binding interface. If there was a 
way to restrict flexibility by binding small molecules, it may be possible to control oncogenic 
protein-protein interactions.  Shown here, a decrease in flexibility in Cdc42 T35A leads to 
altered binding with an effector protein (PBD46).  Since the idea of using small molecules to 
target oncogenic proteins was first conceptualized by Tavares, et al 
80
, recent studies have 





. More needs to be known on how this would affect the overall structure of the protein 
and if it would cause any unwanted/unexpected functional changes. 
Unlike Cdc42 T35A which exhibits a slow exchange rate as a result of decreased 
flexibility, Cdc42 F28L is characterized by an increased exchange rate between GTP and GDP as 
a result of an increase in flexibility 
85
.  Ongoing studies using GTP may provide insight as to 
how the F28L mutation alters the affinity for the nucleotide.  The structure-function relationship 
of this mutant needs to be further studied.  Our lab is able to express and purify the mutant.  
Plans are underway to use DSC to compare the thermal stability of both the GTP- and GDP-
bound forms of Cdc42 T35A with WT.  Any differences might further explain why the fast-
cycling occurs.  GTP hydrolysis assays can also be employed to study the modification on 
hydrolysis in the absence and presence of PBD46.  Pending the outcome of these results, NMR 
can be used to outline the binding interface and identify the changes in the structure-function 
relationship of Cdc42 T35A in comparison to Cdc42 WT. 
4.2 CHARACTERIZATION OF THE INTERACTION BETWEEN RHEB AND TRUNCATED TUBEROUS 
SCLEROSIS COMPLEX 2 CONSTRUCTS 
Rheb differs from other Ras proteins in that it has an intrinsically low rate of GTP 
hydrolysis and requires regulation to prevent overactivity; the activity of TSC2-218 WT as a 
GAP functions to regulate this activity, as shown in Figure 18.  There is no structural 
information to date on TSC2 though protein prediction software predicted the structure of TSC2-
218 to consist of ~25% α helix, ~25% β sheet, and ~50% random coil (Figure 22) 2.  It is of 
upmost importance to determine the structure to be able to fully characterize the TSC2-Rheb 
interaction.  Although efforts in our lab as well as in many other labs to obtain a 2D HSQC of 
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TSC2-218 has proven to be quite difficult 
87
, we will continue to work 
with this protein and attempt to change some aspects of the sample 
preparation in hopes to obtain an acceptable spectrum. The 
TSC2 binding domain of TSC1 has recently been gifted by 
Wenqing Xu (University of Washington).  Based on TSC1’s 
stabilizing role when in complex in TSC2 
63, 64
, pending successful 
transformation, growth and expression, TSC1 may prove to be 
necessary in complex with TSC2-218 in order to determine the 
structure of TSC2-218 WT.  If this proves to be unmanageable, we 
may need to turn our efforts to X-ray crystallography in order to 
get a structure of TSC2-218 for comparison with and without 
Rheb.  
The disease-causing mutant TSC2-218 K114A was shown here to not function as a GAP 
for Rheb (Figure 18), allowing for Rheb to remain in a “locked” GTP-bound active state. The 
biophysical studies presented here lead to the conclusion that the single-point mutation causes 
secondary structure changes that result in an altered interaction with Rheb. Is the loss of binding 
to Rheb a result of a change in conformation that prevents access to the binding site or are the 
molecular details of the binding site altered?  As we begin to understand the chemical and 
biological details of this protein interaction, we now have a platform on which to expand the 
studies of structure-function relationships of these proteins, with particular interest to mutations 
that alter structure and function.   
Figure 22. Structure 
prediction of TSC2-218 
WT using I-TASSER. 
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in full-length TSC2),  is a disease-causing mutation of what is thought to be the catalytic 
asparagine residue required for the asparagine thumb mechanism by which TSC2 increases 
GTPase activity of Rheb 
45, 88
.  The mutation removes an amide group and replaces it with a 
basic amine.  Previous studies of other disease-associated point mutations of the proposed 
catalytic asparagine thumb have eliminated the GAP activity of TSC2 
45
.  Pending successful 
mutation design and expression, we plan to further study and characterize TSC2-Rheb binding 
by studying the N119K mutation in the same manner as the K114A mutation.  
In TSC2, exploration of another disease-causing mutation D1690 (D74 in TSC2-218), 
which lies in a region adjacent to the binding domain, did not inhibit GAP activity towards Rheb 
in vitro 
45
. Unlike with many other mutants studied, it is not clear as to why this mutation is 
disease-causing in vivo.  Is it possibly that this residue is, in part, responsible stabilizing Rheb in 
complex with TSC2?  Further studies on this residue and its importance to TSC2 might reveal a 
new mechanism for oncogenic nature that has not been identified.      
A mutant of Rheb in which the cysteine responsible for farnesylation is mutated to serine, 
thereby removing the free sulfur group, Rheb (C181S), shows a lower GTP level but still 
interacts with TSC2
46, 62
.  Recent work has hypothesized that farnesylation is important for Rheb 
stimulation by GEF and that the GEF is responsible for the decreased ratio of GTP:GDP binding 
50
.  It would be beneficial to identify a Rheb GEF in order to develop ways to block or alter the 




Much still remains unknown about the Rheb/TSC2 interaction, especially directed at TSC2.  
Although multiple studies have been done, there is still no sure answer as to whether TSC1 plays 
a role in TSC2-stimulated GTPase activity of Rheb.  TSC1 has been shown to be required by 
several groups 
53, 55, 62
 while other groups have shown that it is not required 
46, 50
.  What function 
does the TSC1/TSC2 heterodimer display that is different from either TSC1 or TSC2 alone?  It is 
possible that TSC1 is only required for stabilization of TSC2 
63
, but it may play a more 
significant role than has been identified.  Very recently, Tre2-Bub2-Cdc16 1 domain family, 
member 7 (TBC1D7) has been identified as a third core subunit of the TSC1/TSC2 complex and 
preliminary studies have shown that the complex formed (TSC-TBC) functions as a Rheb-GAP 
by sensing cellular growth conditions 
89
. As new information, much more in depth research 
needs to be done to outline and understand completely the interaction and its mechanism. 
4.3 CONCLUSIONS 
Ras-like GTPases are of biological importance for their GTP hydrolysis mechanism; they 
are signal transduction proteins responsible for sending signals to the cell nucleus.  Their role in 
cell signaling cascades will always be the target for studies as long as improper interactions 
occur in vivo that play a role in abnormal cell signaling activities.   
The studies presented here are centered on understanding the relationship that lies between 
structure and function in Ras-related proteins.  Most oncogenic Ras proteins are locked in a 
continuously active state, often facilitated by mutations that alter the intrinsic GTP-hydrolytic 
activity 
90
.  Structural changes imparted by something as small as a single point mutation can 
drastically alter the function of the protein.  The threonine to alanine mutation in Cdc42 led to 
weaker binding and consequently partially restored the hydrolytic activity of Cdc42 in the 
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Cdc42-PBD46 interaction.  As preliminarily seen in the Rheb-TSC2 interaction, the lysine to 
alanine point mutation (K114A) inhibited the interaction, possibly leading to overactivity of 
Rheb and prolonged cell signaling.  Further exploration of these mutations, as well as the 
asparagine to lysine point mutation (N119K) and aspartic acid to alanine mutation (D74A) in 
TSC2-218 and the phenylalanine to leucine mutation (F28L) in Cdc42, are needed for 
characterization of the effects imparted by these mutations on the structure and function of these 
proteins and their interactions as part of a regulatory process. 
A better understanding of the significance of changes on structure in Ras proteins is 
needed; it is necessary to provide a direct link between molecular aspects of interactions between 
proteins and begin to identify ways to regulate or alter aberrant cell signaling.  Hopefully, this 
work can provide a foundation to promote the discovery of molecular features of Ras proteins 
that can aid in the modulation of the interactions that lead to diseased-states.  In order to exploit 
any of these proteins as potential drug targets, much more needs to be understood concerning the 
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